Evidence map›Paper›PMID 35877137›Full record

ArticleBlood advances2022

Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument.

Raj S Kasthuri, Shruti Chaturvedi, Sonia Thomas, Nathan Vandergrift, Carla Bann, Nicole Schaefer, Marianne S Clancy, Reed Pyeritz, Keith R McCrae

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Hereditary haemorrhagic telangiectasia.Nature reviews. Disease primers · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Raj S KasthuriDivision of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0001-6672-3082
Shruti ChaturvediDivision of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Sonia ThomasRTI International, Durham, NC.ORCID 0000-0003-1362-5627
Nathan VandergriftRTI International, Durham, NC.
Carla BannRTI International, Durham, NC.ORCID 0000-0001-9305-8305
Nicole SchaeferCure HHT Foundation, Monkton, MD.
Marianne S ClancyCure HHT Foundation, Monkton, MD.
Reed PyeritzDivision of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and.
Keith R McCraeTaussig Cancer Institute, and.ORCID 0000-0001-7340-475X
RTI International · USCleveland Clinic · USCURE International UK · GBJohns Hopkins University · USUniversity of North Carolina at Chapel Hill · US

Funding

1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)UH3HL140097 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCRAE, KEITH R. · 2020 to 2023
$3.8M
2/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating CenterU24HL140090 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI THOMAS, SONIA M · 2019 to 2023
$2.1M
ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic PurpuraK99HL150594 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHATURVEDI, SHRUTI · 2020 to 2023
$907k
1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)UG3HL140097 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCRAE, KEITH R. · 2019 to 2019
$876k
Efficacy of Pomalidomide in HHT-related bleedingU34HL123416 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCRAE, KEITH R. · 2014 to 2016
$727k
NHLBI NIH HHS K99 HL150594NHLBI NIH HHS U24 HL140090NHLBI NIH HHS U34 HL123416NHLBI NIH HHS UG3 HL140097NHLBI NIH HHS UH3 HL140097
6 · The paper itself

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is characterized by arteriovenous malformations and telangiectasia, with primary clinical manifestations of epistaxis and gastrointestinal bleeding and resultant anemia. HHT negatively affects health-related quality of life (HR-QoL); however, existing tools to measure HR-QoL are not HHT specific. Our objective was to develop an HHT-specific HR-QoL (HHT-QoL) instrument and evaluate its performance in a cross-sectional survey of individuals with HHT. Four HHT-specific questions were developed to evaluate the impact of HHT on productivity and social and personal interactions. An anonymous e-mail survey was conducted through Cure HHT. Participants also indicated their perceived HHT severity and completed 3 Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires: Discretionary Social Activities, Social Roles, and Emotional Distress. Complete data were available for 290 participants who self-identified their HHT severity as mild (29%), moderate (46%), or severe (25%). The HHT-QoL scale was reliable (Cronbach's-α, 0.83). Principal components analysis indicated the instrument was unidimensional. Participants had low levels of QoL with their ability to participate in discretionary social activities (PROMIS mean 36.4 [standard deviation 14.3]) and perform in social roles (41.5 [17.2]), and the presence of a high level of emotional distress (64.8 [24.2]). The HHT-QoL score correlated negatively with PROMIS Discretionary Social Activities (r = -0.65) and Social Roles (r = -0.68) and positively correlated with PROMIS Emotional Distress (r = 0.51). In conclusion, the 4-item HHT-QoL instrument provides valuable insight and may be a useful addition to future clinical research in HHT.

Indexed as

Telangiectasia, Hereditary HemorrhagicCross-Sectional StudiesEpistaxisHumansQuality of LifeSurveys and Questionnaires

Identifiers

PMID35877137
PMCPMC9327531
OpenAlexW3030044676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.